Clofibrate in insulin-dependent diabetes.

Forty-four diabetic patients maintained on insulin entered a doubleblind crossover trial. They were given clofibrate 2 g daily for 6 weeks, either before or after a period of 6 weeks on placebo.Clofibrate did not cause any material change in insulin requirements and there was no change in body weight. Drug tolerance was good.The mean blood glucose was significantly lowered while taking clofibrate. Plasma fibrinogen and pre-beta-lipoprotein concentrations were also significantly decreased following clofibrate therapy.

RCT Entities:   Population Interventions Outcomes